{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-097468","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.473335+00:00","generated_at":"2026-05-30T00:52:51.886007+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OptimizeRx Q3 revenue $21.3M (+30% YoY); GAAP net loss $(9.1)M; guides FY24 rev $88-$92M","bullets":["Q3 revenue $21.3M, up 30% YoY from $16.3M; gross profit $13.4M (+37%); margin 63%.","GAAP net loss $(9.1)M ($(0.50)/share) vs $(2.9)M loss last year; non-GAAP net income $2.3M ($0.12/sh) vs $1.6M.","Adjusted EBITDA $2.7M, up from $0.9M; cash and equivalents $16.1M; paid down $2M on term loan post-quarter.","Updated FY2024 guidance: revenue $88-$92M, Adjusted EBITDA $8-$10M; won 5 DAAP deals in Q3.","Net revenue retention 127% (rolling 12-month); top-20 pharma customers revenue per avg $2.8M vs $1.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-097468","json":"https://secwatch.observer/filing/0001213900-24-097468.json","markdown":"https://secwatch.observer/filing/0001213900-24-097468.md","text":"https://secwatch.observer/filing/0001213900-24-097468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024097468/0001213900-24-097468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024097468/ea0221012-8k_optimize.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:52:51.886007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}